KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.

J Clin Oncol · 2025-May · PMID 39772884

Panel C提取完成待 EXE 对齐验证

OS

FIG 2. OS in patients with (A) nonvisceral or (B) visceral disease a and exploratory analysis in patients with nonvisceral and visceral disease a in the (C) fulvestrant and (D) anastrozole arms. a Visceral disease was defined by the presence of tumors in the adrenal glands, bladder, CNS, esophagus, liver, lung, peritoneum, pleura, kidney, small bowel, stomach, pancreas, thyroid, colon, rectum, ovary, biliary tract, or spleen or by the presence of ascites, or pericardial or pleural effusion. b HR (fulvestrant:anastrozole) <1 favors fulvestrant. Crosses represent censored observations. Data cutoff: July 11, 2022. HR, hazard ratio; mOS, median OS; OS, overall survival.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分1.00
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-18T20:18:41+00:00